NHS trust

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

Retrieved on: 
Vendredi, mai 10, 2024

NICE confirmed that breast cancer patients who are male and trans, non-binary or intersex may benefit from the test depending on their hormonal profile.

Key Points: 
  • NICE confirmed that breast cancer patients who are male and trans, non-binary or intersex may benefit from the test depending on their hormonal profile.
  • Access to genomic testing for patients with lymph node-positive breast cancer addresses the issue of overtreatment with chemotherapy, helping many patients to avoid treatment side effects such as nausea, fatigue, hair loss and potentially secondary cancer.
  • In addition, expanded reimbursement has the potential to free up resources and capacity within NHS breast cancer services.
  • The Oncotype DX Breast Recurrence Score result enables us to do this effectively by providing specific information about an individual’s response to chemotherapy.

Healthcare Executive Angela Single Joins Novari Health

Retrieved on: 
Mardi, novembre 21, 2023

LONDON, Nov. 21, 2023 /PRNewswire/ -- Novari Health is pleased to announce that Angela Single has joined Novari as Director, UK Business Development.

Key Points: 
  • LONDON, Nov. 21, 2023 /PRNewswire/ -- Novari Health is pleased to announce that Angela Single has joined Novari as Director, UK Business Development.
  • Angela is a seasoned executive in the field of digital health.
  • John Sinclair, Chief Executive Officer of Novari Health UK Ltd., commented "Angela's clinical, administrative, and digital health experience make her an invaluable addition to the Novari global team, and we are thrilled to welcome her as our director of UK business development.
  • From its beginnings in Canada in 2003, Novari Health has focused exclusively on helping publicly funded healthcare systems to improve access to care.

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT

Retrieved on: 
Mardi, octobre 31, 2023

CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.

Key Points: 
  • CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.
  • The procedure was conducted by Dr. Nick Smith, D.O., a knee specialist orthopedic surgeon with University Hospitals Coventry and Warwickshire, NHS Trust.
  • "The operation went very well and the patient was discharged the same day with very little postoperative discomfort," said Dr. Nick Smith.
  • The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group.

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT

Retrieved on: 
Mardi, octobre 31, 2023

CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.

Key Points: 
  • CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.
  • The procedure was conducted by Dr. Nick Smith, D.O., a knee specialist orthopedic surgeon with University Hospitals Coventry and Warwickshire, NHS Trust.
  • "The operation went very well and the patient was discharged the same day..." said Dr. Nick Smith.
  • The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group.

Ordr Partners with e-Quip to Deliver Improved Connected Medical Device Visibility and Security for UK Healthcare Market

Retrieved on: 
Mardi, septembre 26, 2023

SANTA CLARA, Calif. and STAFFORD, England, Sept. 26, 2023 /PRNewswire/ -- Ordr, the leader in connected device security, today announced it has partnered with the UK's leading medical device asset management provider Integra e-Quip Ltd. The two companies have teamed up to deliver a best-in-class clinical asset management and security solution to healthcare organizations throughout the UK.

Key Points: 
  • The two companies have teamed up to deliver a best-in-class clinical asset management and security solution to healthcare organizations throughout the UK.
  • Ordr announced it has partnered with the UK's leading medical device asset management provider Integra e-Quip.
  • Ordr's AI-powered platform automatically discovers and classifies all devices connecting to a network, including IoMT (Internet of Medical Things) devices.
  • For more information about how Ordr and e-Quip can help your organization discover and secure every connected medical device, please click here .

Ordr Partners with e-Quip to Deliver Improved Connected Medical Device Visibility and Security for UK Healthcare Market

Retrieved on: 
Mardi, septembre 26, 2023

SANTA CLARA, Calif. and STAFFORD, England, Sept. 26, 2023 /PRNewswire/ -- Ordr, the leader in connected device security, today announced it has partnered with the UK's leading medical device asset management provider Integra e-Quip Ltd. The two companies have teamed up to deliver a best-in-class clinical asset management and security solution to healthcare organizations throughout the UK.

Key Points: 
  • The two companies have teamed up to deliver a best-in-class clinical asset management and security solution to healthcare organizations throughout the UK.
  • e-Quip's Computerised Maintenance Management System (CMMS) maintains an inventory of all connected medical devices on a network, orchestrating critical processes such as device maintenance, procurement planning, and compliance assurance.
  • Ordr's AI-powered platform automatically discovers and classifies all devices connecting to a network, including IoMT (Internet of Medical Things) devices.
  • For more information about how Ordr and e-Quip can help your organization discover and secure every connected medical device, please click here .

Lucy Letby: child murder case highlights need to regulate managers and improve whistleblowing procedures

Retrieved on: 
Vendredi, août 25, 2023

Two medical consultants, Dr Stephen Brearey and Dr Ravi Jayaram, both raised concerns about unexplained infant deaths as early as July 2015.

Key Points: 
  • Two medical consultants, Dr Stephen Brearey and Dr Ravi Jayaram, both raised concerns about unexplained infant deaths as early as July 2015.
  • Common sense would dictate that if a senior doctor raised concerns with managers, even informally, it would be taken seriously.
  • This highlights an urgent need to change the structure of the NHS to ensure managers and executives are held to account for the decisions they make.

Refusal to act

    • In hospitals such as the Countess of Chester, most routine decisions are made by middle management.
    • Brearey and Jayaram suggested that executives were attempting to minimise any reputational damage to the unit and, by extension, the hospital.
    • The decisions of hospital executives will be investigated as part of a public inquiry.

Freedom to Speak Up

    • This is what led to the Freedom to Speak Up review, which investigated how organisations dealt with concerns raised by NHS staff.
    • The results of the report led to the Freedom to Speak Up policy, which provides guidance for NHS staff on how they can raise patient safety concerns.
    • A Freedom to Speak Up Guardian is also now present in every NHS Trust to ensure issues raised are responded to.
    • Even with the Freedom to Speak Up Policy, the British Medical Association reports that staff are still being victimised for raising concerns.
    • Clearly, the policy needs to be improved and legislation passed that would protect staff from dismissal if they do speak up.

First NHS pilot of Ondine Biomedical’s nasal photodisinfection for the prevention of post-surgical infections starts at Mid Yorkshire Teaching NHS Trust

Retrieved on: 
Mardi, août 1, 2023

Mid Yorkshire Teaching NHS Trust has this week started the first UK pilot evaluation of nasal photodisinfection for the prevention of surgical site infections.

Key Points: 
  • Mid Yorkshire Teaching NHS Trust has this week started the first UK pilot evaluation of nasal photodisinfection for the prevention of surgical site infections.
  • The six-month pilot will see 500 elective hip and knee surgery patients nasally decolonized using Ondine Biomedical’s Steriwave® nasal photodisinfection prior to their surgery.
  • Steriwave is already in use at a number of hospitals across Canada, including Vancouver General Hospital and The Ottawa Hospital, and has demonstrated significant improvement in post-surgical outcomes including lower rates of infection, reduced patient length of stay, fewer readmissions, and lower rates of antibiotic prescribing.i,ii,iii
    Dr Stuart Bond, Consultant antimicrobial pharmacist & Director of Innovation at Mid Yorkshire Teaching NHS Trust commented: “We are very pleased to be the first NHS Trust in the UK to pilot this exciting, non-antibiotic method of preventing infections after surgery.
  • Although infections after hip and knee surgeries are rare, we know that they lengthen patients’ stay in hospital, complicate the recovery process, and cause significant pain and suffering.

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Retrieved on: 
Mercredi, juin 28, 2023

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.
  • The radiofrequency energy can be delivered as conventional radiofrequency, cooled radiofrequency or pulsed radiofrequency.
  • "We are extremely pleased with today's interventional procedure recommendation by NICE," commented Dieter Krines, Avanos Vice President & General Manager, Europe.
  • I hope this will now help to increase awareness of this innovative therapy leading to improved outcomes for many more patients."

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Retrieved on: 
Mercredi, juin 28, 2023

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.
  • The radiofrequency energy can be delivered as conventional radiofrequency, cooled radiofrequency or pulsed radiofrequency.
  • "We are extremely pleased with today's interventional procedure recommendation by NICE," commented Dieter Krines, Avanos Vice President & General Manager, Europe.
  • I hope this will now help to increase awareness of this innovative therapy leading to improved outcomes for many more patients."